Right ventricular outfl ow tract revalvulation using the Melody Valve: The next frontier in terms of years of freedom from re-operation. Freedom from re-operation varies (see Table I ) with rates of 97% at one year to, on average, 70% and 31% after 10 and 15 years respectively. (1) (2) (3) Low body weight, younger age at insertion, small size grafts and longer cross-clamping times are factors associated with early graft failure. (1, 4) It has been estimated that these patients may require up to 5 conduit revisions over a lifetime.
INTRODUCTION
Various congenital heart lesions with anatomical abnormalities involving the right ventricular outflow tract (RVOT) will require surgical repair early in childhood. Classical lesions include tetralogy of Fallot, pulmonary atresia and truncus arteriosus. A significant number of these will, over time, develop additional problems of the RVOT which will need to be addressed in order to prevent right ventricular dysfunction.
SURGICAL REVALVULATION
Surgery has been the preferred method of establishing RVOT revalvulation. It has traditionally been reserved for children older than 3 years. Surgical revalvulation consists of the implantation of allo-or xenografts. Pulmonary homografts are generally preferred, but other valves e.g. Contegra ® or prosthetic conduits are also being used. Due to improvements in surgical techniques, mortality for re-operation has declined and is now in the region of 3.7%.
However, failure of the conduit eventually occurs because of limited longevity. Conduit degeneration is observed in more than 75% of homografts over time. Lifespan of conduits are measured 
CURRENT INDICATIONS FOR PERCUTANEOUS

PULMONARY VALVE IMPLANTATION
Only patients meeting indications for surgical re-intervention qualify for consideration of valve implantation. Clinical and morphological indications and contraindications for Melody ® valve implantation can be viewed in Table 2 .
DIAGNOSTIC EVALUATION
Patients with right ventricle to pulmonary artery (RV-PA) conduit dysfunction need to be evaluated for possible percutaneous pulmonary valve implantation (PPVI). ECG holter is performed to identify possible arrhythmias and for calculation of QRS intervals.
Objective functional assessment to determine exercise capacity can be done by measuring the peak oxygen uptake (VO2max) and anaerobic threshold derived from respiratory gas analysis during maximal exercise testing. (7) (8) (9) Transthoracic echocardiography is used to determine right ventricular pressure load, size and categorical assessment of pulmonary regurgitation. However, echocardiographic right ventricular functional assessment does not correlate well with cardiac magnetic resonance imaging (MRI). (10, 11) Pulmonary regurgitation severity should be assessed and classified.
RVOT anatomy, RV-PA mean gradients, mitral-and tricuspid regurgitant jets can yield valuable information. (8) (9) (10) (11) High resolution computed tomography (CT) angiography of the RVOT gives important information regarding RVOT anatomy and the spatial relationship to the coronary arteries. (8) CT angiography does, however, have added radiation exposure compared to MRI. Cardiac MRI gathers valuable information regarding ventricle mass, function and volumes and is currently the preferred investigation. (7, 8, 13) TECHNICAL ASPECTS OF RVOT REVALVULATION
BY MEANS OF THE MELODY ® VALVE
The Melody ® valve consists of a segment of modified-bovine jugular vein sutured into a platinum iridium stent of 34mm in length. The valve can be crimped down to 6mm and re-expanded from a minimum of 18mm to a maximum of 22mm ( Figure 1A ).
Delivery system
The Ensemble transcatheter delivery system was designed for percutaneous Melody ® valve implantation and consists of a balloonin-balloon structure with a retractable sheath for valve covering post crimping. The system is 100cm in length and has an outer diameter of 22Fr size ( Figure 1B ). 
FIGURE 4: Post valve implantation angiogram
Angiogram in pulmonary artery distal to newly implanted valve demonstrates no pulmonary regurgitation.
FIGURE 3: Melody ® valve expanded
The Melody ® valve delivered into the prestented RVOT. Note the distal tip of Ensemble delivery system.
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Volume 10 • Number 2 metal stent for pre-stenting will be influenced by the risks of homograft rupture. Most operators would nowadays prefer to use a long covered stent (≥45mm) in a homograft since calcified, crimped homografts fracture if dilated. In these patients flaring proximal and distal ends to appose tightly to the surrounding tissues at the proximal and distal anastomsis would be important.
It is essential to create a stable Melody ® landing site and any recoil during pre-stenting should lead to additional stenting. It is important to note that any residual RVOT gradient >15mmHg should not be accepted prior to valve deployment.
Once RVOT rehabilitation has been performed, the Melody ® valve is delivered in an appropriate position (Figure 3 ). Repeat hemodynamic assessment and angiography are performed to evaluate the result (Figure 4 ). Residual gradients can be treated with high pressure balloon dilatation after valve implantation. Cardiothoracic backup is desirable during the procedure.
OUTCOMES OF PERCUTANEOUS PULMONARY
VALVE IMPLANTATION
More than 3 000 valves have been implanted worldwide and overall mortality is very low (0% -1%). (7, 10, 12, (14) (15) (16) (17) Procedural success for attempted percutaneous valve implantation is excellent. The most common exclusion factor has been the risk of coronary compression. Significant reduction in outflow tract gradient and/or abolishment of pulmonary regurgitation was observed in all cases. Right ventricular volumes also improved markedly.
Major procedural complications included dislodgement of the valve, coronary compression, rupture of homograft and haemothorax due to pulmonary artery perforations. (7, (13) (14) (15) (16) (17) (18) Dislodgement of the device occurred mostly during the initial development phase and could be related to operator inexperience as well as the early learning curve. It is now extremely rare, especially with pre-stenting.
Coronary compression was responsible for virtually all deaths
resulting from percutaneous revalvulation. Since this is a potentially avoidable complication, pre-selection with sophisticated imaging modalities as mentioned have become essential. Rupture of homograft conduits is a rare, but ever present risk. Therefore, making routine use of a covered stent or at least having one of these available during the procedure is essential. The pulmonary arteries may be perforated by the very stiff guidewires employed to deliver the valve. In the worldwide experience, some resolved spontaneously, could be treated by implanting a covered stent to seal off the perforation or required a thoracotomy. Overall, early complications were rare during percutaneous procedures, occurring in less than 8.5% of implantations. (8, 16, 17) This compares favorably to surgical series where early complications have been described in up to 9.6% of patients. (18) Follow-up results for outcome are now short to mid-term. The most common complication has been stent fractures which occurred in 5% to 30% of cases. (14, 15, 19) Although the vast majority of stent fractures remain asymptomatic, it may lead to the development of outflow tract gradients. However, this can easily be treated with the implantation of another percutaneous valve. This problem is likely to decrease due to the current practice of routine right ventricular outflow tract pre-stenting. Although extremely rare, endocarditis is a vexing problem and the most common reason for valve explantation. (20) Freedom from valve dysfunction or re-operation ranged from 95 -100% at one year to 70% at seventy months during followup. (8, 14, 15) These results provide evidence that the initial aim of prolonging the life-span of surgically placed right ventricular outflow tract conduits can be successfully achieved by the implantation of a percutaneous valve.
Cost analyses have been favourable. Although the valve itself is expensive, the low morbidity and short hospital stay makes total cost comparable to that of surgery. (21) It should be pointed out that cost comparisons for South Africa are currently not available.
The main benefits of percutaneous pulmonary valve implantations are the low risks, short hospital stays, delay in the need for surgery and improvement in quality of life.
TIMING OF RIGHT VENTRICLE OUTFLOW TRACT
REVALVULATION: THE CONTROVERSY
Right ventricular outflow tract dysfunction is one of the most common killers in congenital heart diseases. Although the indications for intervention in stenosis are clearly defined, the same cannot be said for pulmonary valve regurgitation. As a matter of fact, it is a well-established fact that some patients with pulmo- Compare this to patients with right ventricular outflow tract dysfunction -we know that it leads to right heart dilation and that a significant number die unexpectedly due to arrhythmias. Furthermore, these dilated right ventricles have normal or near normal function on MRI. All these findings suggest that electrical and cellular level dysfunction set in long before global mechanical dysfunction becomes apparent. If we allow too much time to pass before revalvulation, irreparable damage may occur to the right ventricle explaining the poor results of revalvulation in some patients. In the past, physicians tended to wait as long as possible before intervening due to the risks and morbidity associated with surgery. In this new era of percutaneous valves, one may thus consider revalvulation at an earlier age in order to preserve right ventricular mechanics. As a result, some physicians advocate intervention in these patients before they become symptomatic. However, at present we still do not have the ability to accurately measure when it is time to intervene in asymptomatic patients and the timing of intervention is bound to remain controversial until we can scientifically define measureable right ventricle parameters to guide the decision.
FUTURE DEVELOPMENTS
New developments consist of mounting valves on stronger stents and a new version of the Melody ® valve will soon become available. Also, valves are being developed for larger outflow tracts which cannot be treated with the current valve sizes available. This has been a limiting factor in some patients, especially patients with dilated outflow tracts. Recent studies have also shown that the valve can be implanted in selected cases in younger patients (<20kg) and has even been used during hybrid procedures to avoid cardiac bypass. (24) Surgeons are also adapting techniques at initial procedures to construct conduit angles amenable to transcatheter intervention and at a safe distance from the coronary arteries.
CONCLUSION
Percutaneous pulmonary valves are a safe and effective therapy for revalvulation of the right ventricular outflow tract. The stented valves can be implanted with a high success rate as well as low morbidity and mortality. Results have proven that percutaneous pulmonary valves extend the lifespan of conduits. It is important to realise that percutaneous revalvulation is complimentary to surgery and not in competition with surgical revalvulation. The availability of percutaneous valves may change the way in which we approach right ventricular revalvulation in the future, but remains controversial at present for certain indications.
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